A Study for Patients With Acute Leukemia

Inclusion Criteria

• •Dose escalation period for both schedules:
• •Participants must have a confirmed diagnosis of acute leukemia regardless of sub-type and for whom experimental Phase 1 therapy is appropriate.
• •Are greater than or equal to 18 years of age.
• •Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
• •Females with childbearing potential must have had a negative urine or serum pregnancy test less than or equal to 7 days prior to the first dose of study drug.
• •Dose confirmation period for both schedules:
• •Participant must have a confirmed diagnosis of untreated acute myeloblastic leukemia (AML), should not be a candidate for standard therapy, and a clinical trial is a preferred treatment option or have acute AML that is relapsed or refractory to no more than 2 prior induction regimens. Hydroxyurea to control prior blast counts is not considered a prior regimen.
• •Are greater than or equal to 60 years of age.
• •Have a performance status of 0 or 1 on the ECOG scale.
• •Females with childbearing potential must have had a negative urine or serum pregnancy test less than or equal to 7 days prior to the first dose of study drug.